Sudeep Pharma Limited · NSE:SUDEEPPHRM
Sudeep Pharma — Q1 FY27 Earnings Presentation
37 slides from Sudeep Pharma's earnings presentation, Aug 4, 2026
Slide 1: Stock exchange cover letter for Q1FY27 result presentation
Date: 4th August 2026 To, National Stock Exchange of India Limited BSE Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Bandra Kurla Dalal Street, Mumbai – 400001 Complex, Bandra (E), Mumbai – 400051 Scrip Code: 544619 Scrip Symbol- SUDEEPPHRM Sub: Q1FY27 - Result Presentation Ref: Reg
Slide 2: Sudeep Pharma Limited Investor Presentation August 2026
Sudeep Pharma Limited Investor Presentation August 2026
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sudeep Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securit
Slide 4: Q1 FY27 Performance Highlights
Q1 FY27 Performance Highlights
Slide 5: MD's Message
MD’s Message "We are pleased to report a strong start to FY27, with revenue growing 27% year-on-year, driven by broad-based performance across our Pharma, Food & Nutrition, and Specialty Ingredients businesses. The quarter was marked by a challenging global environment characterised by geopolitical
Slide 6: Q1 FY27 Performance Highlights
Q1 FY27 Performance Highlights Revenue from Operations EBITDA & Margin % PAT & Margin % Rs. Cr. Rs. Cr. Rs. Cr. 35.1% 34.7% 34.6% 25.0% 25.6% 27.1% 642.3 221.9 174.3 +27% +25% +30% 124.9 158.3 54.9 43.9 31.3 40.6 Q1FY26 Q1FY27* FY26* Q1FY26 Q1FY27* FY26* Q1FY26 Q1FY27* FY26* Revenue Breakup % Geogra
Slide 7: Q1 FY27 Key Highlights
Q1 FY27 Key Highlights • Revenue from operations for Q1FY27 stood at Rs. 158.3 Cr, registering a strong 27% year-on-year growth despite multiple challenges like geopolitical uncertainties, intermittent gas supply constraints, elevated logistics costs, and continued container shortages across key tra
Slide 8: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (Rs. Crs) Q1FY27* Q1FY26 YoY FY26* Revenue from Operations 158.3 124.9 27% 642.3 Cost of materials consumed 56.6 42.3 227.3 Employee Expenses 14.3 12.2 51.9 Other Expenses 32.4 26.5 141.2 EBITDA 54.9 43.9 25% 221.9 EBITDA Margin (%) 34.7% 35.1% 34.6%
Slide 9: Battery Materials - Ground Breaking Ceremony of Land in Dahej, Gujarat
Battery Materials - Ground Breaking Ceremony of Land in Dahej, Gujarat Successfully conducted the groundbreaking ceremony for Battery Materials Plant at Dahej on January 23, 2026. Setting up plant at Dahej, Gujarat • Project cost: Appx. Rs 300 crores • Expect completion by early CY27 • Mode of Finan
Slide 10: Capacity Expansion & Strategic Validation
Capacity Expansion & Strategic Validation Strategic Positioning: Emerging as a premier reliable non-Chinese supplier for battery-grade iron phosphate PCAM. Manufacturing Scale: Global Presence in Dominant Battery Markets Phase 1: 44 28 Customers across South Korea, Japan, Indonesia, Europe, USA, & A
Slide 11: Company Overview
p Pharma Limited s Sudee Company Overview
Slide 12: Sudeep Pharma at a Glance
Sudeep Pharma at a Glance Founded in 1989, 3+ decades of experience in 35 Years of Expertise in vitamins & mineral chemistries* 5 Manufacturing Sites ^ Specialty Chemistries Metric Tones (“MT”) Fortune 500 Companies1 Leading player in the Excipients & 14 as customers ~1,23,000 + Annual Manufacturing
Slide 13: Our Journey from Pharma Excipients to Specialty Ingredients Manufacturer
Our Journey from Pharma Excipients to Specialty Ingredients Manufacturer 2025 2024 2021–2023 2015–2022 Strategic 1989 Acquisitions & Diversification & IPO Readiness Ownership Innovation and Consolidation Global Portfolio Foundation & Partnerships & Expansion Early Market Entry Operations 2024 2025 2
Slide 14: Corporate Structure
Corporate Structure Sudeep Pharma Limited (Holding) Sudeep Nutrition Private Ltd. Sudeep Pharma USA Inc. Sudeep Pharma B.V. Sudeep Advanced Materials (Wholly Owned Subsidiary) (Wholly Owned Subsidiary) (Wholly Owned Subsidiary) (Wholly Owned Subsidiary) 85% Ownership 13
Slide 15: One of the World's Leading and Trusted Manufacturer
One of the World’s Leading and Trusted Manufacturer The Start At Present 2020 2021 2023 2024 2025 Ireland Manufacturing 5 Site¹ Manufacturing Sites^ Europe Sales Office – The HQ - Vadodara, Netherlands² Gujarat³ 100+ Products 4 Manufacturing USA Sales Office - New Sites, India ⁴ Jersey² Mumbai Offic
Slide 16: Strengths - Core Competencies and USP's
Strengths - Core Competencies and USP’s Innovation Engineered Through Proprietary Technologies Leadership in High Barrier Industry, Diversified Product Portfolio 6 indigenously developed technologies 100+ Products across different verticals Encapsulation Spray Drying Granulation Liposomal Trituratio
Slide 17: Key Value Propositions
Key Value Propositions 1. Market Leadership with 6. Distinguished global customer Diversified Product Portfolio base with long standing relationships with Key Customers 2. High Entry Barriers 7. Proven Credentials and Leading Accolades Key 3. Well-Equipped & Regulatory Compliant Manufacturing Value
Slide 18: 1. Market Leadership with Diversified Product Portfolio
1. Market Leadership with Diversified Product Portfolio Delivering Products that Matter Pharmaceutical, Food & Nutrition Speciality Ingredients Battery Materials Mineral Micro-nutrient Liposomal Fillers Ingredients Battery-Grade Iron Phosphate* Fortificants Premixes pCAM for LFP (Lithium Iron Phosph
Slide 19: 2. High Entry Barriers
2. High Entry Barriers Cost Split of a Tablet Composition split of a Tablet ~5% Excipients ~95% API ~95% Excipients ~5% API Low Cost but High Functionality Disintegration & Tablet Performance^ Stability of Tablet^ Dissolution^ Product Range Tailored to Meet the Precise Needs of Customers in a High B
Slide 20: 3. Well-Equipped & Regulatory Compliant Manufacturing Facilities
3. Well-Equipped & Regulatory Compliant Manufacturing Facilities Unit I – Nandesari Unit II – Nandesari 12 Set Up 1989 Set Up 2011 Production Lines Calcium Carbonate - Powder, Tricalcium Phosphate, Dicalcium Products Oxides, Carbonates, Sulphates Products Phosphate, Iron Phosphate, Magnesium Stearat
Slide 21: 4. Proprietary Technologies
4. Proprietary Technologies Encapsulation Spray Drying Granulation Blending Liposomal Preparation Trituration Expertise In: Extending Product Shelf-life Target, Controlled and Sustained Release Address Taste and Odor Challenges Particle Engineering Enhance Ingredient Bio-Availability Improved Produc
Slide 22: 5. Strong Research & Development Capabilities
5. Strong Research & Development Capabilities R&D Expenses (% of Revenue from Operations) 1.96% 1.71% 41 R&D Personnel 6 Proprietary Technologies 1.66% 0.91% FY23 FY24 FY25 FY26 R&D Initiatives Assist in^ : • Extending Product Shelf-Life & Vitality • Ensuring Targeted release of excipients • Underta
Slide 23: 6. Distinguished global customer base with long standing relationships
6. Distinguished global customer base with long standing relationships with Key Customers 14 ^ 1,120+ 8% Global Fortune 500 Single Largest Customers served^ companies as customers^ Customer ~100 Countries Global presence ^ ^ 40+ 25% 32% ~7 Years Top 10 Blue-chip multinational Top 5 Customers Avg. te
Slide 24: 7. Proven Credentials and Leading Accolades
7. Proven Credentials and Leading Accolades Key Awards Key Certifications FRK Manufacturing Customer Centric Excellence Business Partner Award Award By Millers for By Abbott Nutrition Suppliers Excellence in Summit 2023 Innovative Award Ingredients Manufacturing By Herbalife By Nutrition ASSOCHAM Gl
Slide 25: 8. Experienced Board and Senior Management Team
8. Experienced Board and Senior Management Team Promoters & Directors Board Members Mrs. Reshma Suresh Patel (Independent Director) Mr. Ajay Kandelkar- Director of Operations Graphical Arts Technical Foundation, Pittsburgh Dairy technology from Dr. Panjabrao Deshmukh KV Prior directorship- Shreno Pu
Slide 26: 9. Healthy Improvement in Performance with Disciplined Balance Sheet
9. Healthy Improvement in Performance with Disciplined Balance Sheet Revenue from Operations EBITDA & Margin % Rs. Cr. Rs. Cr. 20.8% 39.6% 37.8% 34.6% +14% 642.3 502.0 +36% 428.7 459.3 221.9 181.7 190.0 89.1 FY23 FY24 FY25 FY26* FY23 FY24 FY25 FY26* PAT & Margin % Net Debt & Net Debt / Equity (x) Rs
Slide 27: 10. Backed by Healthy Growth in End User Industries
10. Backed by Healthy Growth in End User Industries Battery Speciality Ingredients Pharmaceutical Excipients Chemicals Food Nutritional Encapsulated Micronutrient Granulated Global India Global Market Ingredients Ingredients Ingredients Ingredients Ingredients Excipients Excipients Market Size USD 8
Slide 28: Growth Levers
n ro o > ® al ra s S ) = 10)
Slide 29: Key Capacity Expansion
Key Capacity Expansion Capacity Visibility (in MT)* FY27 Key Segments FY25 FY26 FY28e FY29-30e Existing 1) Pharma, Food & Nutrition 35,000 35,000 86,200 86,200 86,200 - Greenfield Project Addition 51,200 2) Speciality Ingredients 30,000 37,500 37,500 37,500 37,500 - NSS Capacity Addition 7,500 3) Ba
Slide 30: 1. Organic Growth – Upcoming Greenfield Expansion
1. Organic Growth – Upcoming Greenfield Expansion Upcoming Greenfield at Nandesari, Gujarat Location Total Capex Capacity Nandesari GIDC, Vadodara Gujarat ~ 150 Crores INR 51,200 MT Annually Focused Segment Mode of Financing Commissioning Status Pharmaceutical Excipients, Actives and Internal Accrua
Slide 31: 2. Organic Growth – Leveraging Mineral Chemistry Expertise for Battery Materials
2. Organic Growth – Leveraging Mineral Chemistry Expertise for Battery Materials Key Pillar Our Advantage Leveraging Decade of expertise in Iron Phosphate FEOC-Compliant Supply Fully aligned with FEOC compliance norms, helping customers meet regulations Chain under the US IRA & EU Critical Raw Mater
Slide 32: 3. Inorganic Growth – Vitamin & Mineral Blends Business Acquisition
3. Inorganic Growth – Vitamin & Mineral Blends Business Acquisition Integrate Recently Acquired Entities & Continue Evaluating Inorganic Growth Opportunities Acquired 85.00% Engaged in business of manufacturing of vitamin & mineral blends in form May 2025 of dry blends, water soluble blends, oil sol
Slide 33: Historical Financial Statements
Historical Financial Statements
Slide 34: Historical Profit & Loss Statement
Historical Profit & Loss Statement Particulars (Rs. Crs) FY26* FY25 FY24 FY23 Revenue from Operations 642.3 502.0 459.3 428.7 Cost of materials consumed 227.3 164.8 165.3 182.5 Employee Expenses 51.9 38.3 29.4 66.1 Other Expenses 141.2 108.9 82.9 91.1 EBITDA 221.9 190.0 181.7 89.1 EBITDA Margin (%)
Slide 35: Historical Balance Sheet Statement
Historical Balance Sheet Statement Assets (Rs. Crs) Mar-26* Mar-25 Mar-24 Mar-23 Equity & Liabilities (Rs. Crs) Mar-26* Mar-25 Mar-24 Mar-23 Non - Current Assets 550.9 293.1 238.5 190.1 Total Equity 898.1 493.1 356.0 223.3 Property, plant and equipment 224.0 177.1 167.0 149.4 Equity share capital 11
Slide 36: Historical Cash Flow Statement
Historical Cash Flow Statement Particulars (Rs. Crs) Mar-26* Mar-25 Mar-24 Mar-23 Net Profit Before Tax 228.1 182.8 174.8 86.0 Adjustments for: Non -Cash Items / Other Investment or Financial Items 9.0 15.5 13.5 17.9 Operating profit before working capital changes 237.1 198.3 188.3 103.9 Changes in
Slide 37: Thank You!
Thank You! Company Details: Investor Relations Advisor : Strategic Growth Advisors Pvt. Ltd. Sudeep Pharma Ltd. CIN - U74140MH2010PTC204285 CIN – L24231GJ1989PLC013141 Mr. Shrikant Sangani / Ms. Shaily Patwa Ms. Dimple Mehta – Company Secretary Email - shrikant.sangani@sgapl.net / shaily.p@sgapl.net